{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:12:54Z","timestamp":1789693974662,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11060-021-03719-5","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T08:02:55Z","timestamp":1614585775000},"page":"515-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4317-5770","authenticated-orcid":false,"given":"Mary Jane","family":"Lim-Fat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun Wei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bryan","family":"Iorgulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Forst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Gerstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Reardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Arrillaga-Romany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"3719_CR1","doi-asserted-by":"publisher","first-page":"iv","DOI":"10.1093\/neuonc\/noaa200","volume":"22","author":"QT Ostrom","year":"2020","unstructured":"Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013\u20132017. Neuro Oncol 22:iv. https:\/\/doi.org\/10.1093\/neuonc\/noaa200","journal-title":"Neuro Oncol"},{"issue":"8","key":"3719_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","volume":"22","author":"PY Wen","year":"2020","unstructured":"Wen PY, Weller M, Lee EQ et al (2020) Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22(8):1073\u20131113. https:\/\/doi.org\/10.1093\/neuonc\/noaa106","journal-title":"Neuro Oncol"},{"issue":"12","key":"3719_CR3","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1001\/jamaoncol.2020.4937","volume":"6","author":"N Lamba","year":"2020","unstructured":"Lamba N, Chukwueke UN, Smith TR et al (2020) Socioeconomic disparities associated with MGMT promoter methylation testing for patients with glioblastoma. JAMA Oncol 6(12):1972\u20131974. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4937","journal-title":"JAMA Oncol"},{"issue":"2","key":"3719_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RGW, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155(2):462. https:\/\/doi.org\/10.1016\/j.cell.2013.09.034","journal-title":"Cell"},{"issue":"5","key":"3719_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/PAS.0b013e31827f9c5e","volume":"37","author":"BK Kleinschmidt-Demasters","year":"2013","unstructured":"Kleinschmidt-Demasters BK, Aisner DL, Birks DK, Foreman NK (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37(5):685\u2013698. https:\/\/doi.org\/10.1097\/PAS.0b013e31827f9c5e","journal-title":"Am J Surg Pathol"},{"issue":"20","key":"3719_CR6","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877\u20131888. https:\/\/doi.org\/10.1056\/NEJMoa1406037","journal-title":"N Engl J Med"},{"issue":"1","key":"3719_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2017.7032","volume":"16","author":"TM Johanns","year":"2018","unstructured":"Johanns TM, Ferguson CJ, Grierson PM, Dahiya S, Ansstas G (2018) Rapid clinical and radiographic response with combined dabrafenib and trametinib in adults with BRAF-mutated high-grade glioma. JNCCN J Natl Compr Cancer Netw 16(1):4\u201310. https:\/\/doi.org\/10.6004\/jnccn.2017.7032","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"4","key":"3719_CR8","doi-asserted-by":"publisher","first-page":"343","DOI":"10.6004\/jnccn.2017.7052","volume":"16","author":"KC Schreck","year":"2018","unstructured":"Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA (2018) Concurrent BRAF\/MEK inhibitors in BRAF V600-Mutant high-grade primary brain tumors. JNCCN J Natl Compr Cancer Netw 16(4):343\u2013347. https:\/\/doi.org\/10.6004\/jnccn.2017.7052","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"issue":"2","key":"3719_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/neuonc\/not146","volume":"16","author":"S Dahiya","year":"2014","unstructured":"Dahiya S, Emnett RJ, Haydon DH et al (2014) BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 16(2):318\u2013319. https:\/\/doi.org\/10.1093\/neuonc\/not146","journal-title":"Neuro Oncol"},{"issue":"21","key":"3719_CR10","doi-asserted-by":"publisher","first-page":"e2483","DOI":"10.1212\/WNL.0000000000007529","volume":"92","author":"BM Andersen","year":"2019","unstructured":"Andersen BM, Miranda C, Hatzoglou V, Deangelis LM, Miller AM (2019) Leptomeningeal metastases in glioma: the Memorial Sloan Kettering Cancer Center experience. Neurology 92(21):e2483\u2013e2491. https:\/\/doi.org\/10.1212\/WNL.0000000000007529","journal-title":"Neurology"},{"issue":"4","key":"3719_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/00006123-199010000-00002","volume":"27","author":"FT Vertosick","year":"1990","unstructured":"Vertosick FT, Selker RG (1990) Brain stem and spinal metastases of supratentorial glioblastoma multiforme. Neurosurgery 27(4):516. https:\/\/doi.org\/10.1097\/00006123-199010000-00002","journal-title":"Neurosurgery"},{"issue":"5","key":"3719_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/emmm.201000070","volume":"2","author":"D Dias-Santagata","year":"2010","unstructured":"Dias-Santagata D, Akhavanfard S, David SS et al (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2(5):146\u2013158. https:\/\/doi.org\/10.1002\/emmm.201000070","journal-title":"EMBO Mol Med"},{"issue":"6","key":"3719_CR13","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","volume":"141","author":"EP Garcia","year":"2017","unstructured":"Garcia EP, Minkovsky A, Jia Y et al (2017) Validation of oncopanel a targeted next-generation sequencing assay for the detection of somatic variants in cancer. Arch Pathol Lab Med 141(6):751\u2013758. https:\/\/doi.org\/10.5858\/arpa.2016-0527-OA","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"3719_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","volume":"139","author":"DJ Brat","year":"2020","unstructured":"Brat DJ, Aldape K, Colman H et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139(3):603\u2013608. https:\/\/doi.org\/10.1007\/s00401-020-02127-9","journal-title":"Acta Neuropathol"},{"key":"3719_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-016-0506-2","author":"F Behling","year":"2016","unstructured":"Behling F, Barrantes-Freer A, Skardelly M et al (2016) Frequency of BRAF V600E mutations in 969 central nervous system neoplasms. Diagn Pathol. https:\/\/doi.org\/10.1186\/s13000-016-0506-2","journal-title":"Diagn Pathol"},{"issue":"4","key":"3719_CR16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall S, Zapotocky M, Fukuoka K et al (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37(4):569-583.e5. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.011","journal-title":"Cancer Cell"},{"issue":"5","key":"3719_CR17","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/bpa.12566","volume":"28","author":"A Korshunov","year":"2018","unstructured":"Korshunov A, Chavez L, Sharma T et al (2018) Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. Brain Pathol 28(5):656\u2013662. https:\/\/doi.org\/10.1111\/bpa.12566","journal-title":"Brain Pathol"},{"key":"3719_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2019.08.007","author":"VM Lu","year":"2019","unstructured":"Lu VM, George ND, Brown DA et al (2019) Confirming diagnosis and effective treatment for rare epithelioid glioblastoma variant: an integrated survival analysis of the literature. World Neuroncol. https:\/\/doi.org\/10.1016\/j.wneu.2019.08.007","journal-title":"World Neuroncol"},{"key":"3719_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","volume":"9","author":"M Mistry","year":"2015","unstructured":"Mistry M, Zhukova N, Merico D et al (2015) BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 9:1015\u20131022. https:\/\/doi.org\/10.1200\/JCO.2014.58.3922","journal-title":"J Clin Oncol"},{"issue":"4","key":"3719_CR20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00401-019-01987-0","volume":"137","author":"DW Ellison","year":"2019","unstructured":"Ellison DW, Hawkins C, Jones DTW et al (2019) cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathol 137(4):683\u2013687. https:\/\/doi.org\/10.1007\/s00401-019-01987-0","journal-title":"Acta Neuropathol"},{"key":"3719_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.03.011","author":"S Ryall","year":"2020","unstructured":"Ryall S, Zapotocky M, Fukuoka K, Ellison DW, Tabori U, Hawkins Correspondence C (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.011","journal-title":"Cancer Cell"},{"issue":"3","key":"3719_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/nan.12093","volume":"40","author":"A Broniscer","year":"2014","unstructured":"Broniscer A, Tatevossian RG, Sabin ND et al (2014) Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathol Appl Neurobiol 40(3):327\u2013336. https:\/\/doi.org\/10.1111\/nan.12093","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"24","key":"3719_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/BF01476415","volume":"126","author":"N Arita","year":"1994","unstructured":"Arita N, Taneda M, Hayakawa T (1994) Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126(24):84\u201392. https:\/\/doi.org\/10.1007\/BF01476415","journal-title":"Acta Neurochir (Wien)"},{"issue":"6","key":"3719_CR24","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.3892\/or.2017.6013","volume":"38","author":"MC Burger","year":"2017","unstructured":"Burger MC, Ronellenfitsch MW, Lorenz NI et al (2017) Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncol Rep 38(6):3291\u20133296. https:\/\/doi.org\/10.3892\/or.2017.6013","journal-title":"Oncol Rep"},{"issue":"9839","key":"3719_CR25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","volume":"380","author":"A Hauschild","year":"2012","unstructured":"Hauschild A, Grob JJ, Demidov LV et al (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380(9839):358\u2013365. https:\/\/doi.org\/10.1016\/S0140-6736(12)60868-X","journal-title":"Lancet"},{"issue":"7","key":"3719_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D et al (2019) Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med 381(7):626\u2013636. https:\/\/doi.org\/10.1056\/NEJMoa1904059","journal-title":"N Engl J Med"},{"key":"3719_CR27","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/JCO.2018.78.9990","volume":"36","author":"T Kaley","year":"2018","unstructured":"Kaley T, Touat M, Subbiah V et al (2018) BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol 36:3477\u20133484. https:\/\/doi.org\/10.1200\/JCO.2018.78.9990","journal-title":"J Clin Oncol"},{"key":"3719_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/po.19.00272","volume":"4","author":"M Kushnirsky","year":"2020","unstructured":"Kushnirsky M, Feun LG, Gultekin SH, de la Fuente MI (2020) Prolonged complete response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutant glioblastoma. JCO Precis Oncol 4:44\u201350. https:\/\/doi.org\/10.1200\/po.19.00272","journal-title":"JCO Precis Oncol"},{"key":"3719_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/neuonc\/noy148.986","volume":"20","author":"P Wen","year":"2018","unstructured":"Wen P, Alexander S, Yung-Jue B et al (2018) Rare-09. Efficacy and safety of dabrafenib + trametinib in patients with recurrent\/refractory braf v600e\u2013mutated high-grade gliomA (HGG). Neuro Oncol 20:238. https:\/\/doi.org\/10.1093\/neuonc\/noy148.986","journal-title":"Neuro Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03719-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03719-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T17:17:10Z","timestamp":1619716630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03719-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3719"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03719-5","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"8 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.J. Lim-Fat; K.W. Song; B.M. Andersen; D.A. Forst; E.R. Gerstner and I. Arrillaga-Romany report no disclosures relevant to the manuscript; J.B. Iorgulescu received support from the NIH (NCI K12CA090354) and Conquer Cancer Foundation\/Sontag Foundation Young Investigator Award; J.T. Jordan received honoraria from Elsevier and Consulting for Navio Theragnostics, Recursion Pharmaceuticals, CereXis, Inc, and Health2047, Inc; D.A. Reardon received Research support (paid to DFCI) fromAcerta Phamaceuticals; Agenus; Celldex; EMD Serono; Incyte; Inovio; Midatech; Omniox; Tragara, advisory\/consultation (paid to Dr. Reardon): Abbvie; Advantagene; Agenus; Amgen; Bayer; Bristol-Myers Squibb; Celldex; DelMar; EMD Serono; Genentech\/Roche; Imvax; Inovio; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; Taiho Oncology, Inc., Honoraria (paid to Dr. Reardon): Abbvie; Advantagene; Agenus; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech\/Roche; Imvax; Inovio; Merck; Merck KGaA; Monteris; Novocure; Oncorus; Oxigene; Regeneron; Stemline; Taiho Oncology, Inc; P.Y. Wen received honoraria from Agios, Astra Zeneca\/Medimmune, Beigene, Celgene, Eli Lily, Genentech\/Roche, Kazia, MediciNova, Merck, Novartis, Oncoceutics, Vascular Biogenics, VBI Vaccines (research support); Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, CNS Pharmaceuticals, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, VBI Vaccines, Tocagen, Voyager, QED, Imvax, Elevate Bio (advisory board) and Merck, Prime Oncology (speaker honoraria).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted under a Dana-Farber\/Harvard Cancer Center Institutional Review Board protocol. A waiver was granted for informed consent due to its retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}